Search

Your search keyword '"Cannistra SA"' showing total 157 results

Search Constraints

Start Over You searched for: Author "Cannistra SA" Remove constraint Author: "Cannistra SA"
157 results on '"Cannistra SA"'

Search Results

Catalog

Books, media, physical & digital resources

17. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo

18. Differential expression of HLA-DR antigens in subsets of human CFU-GM

19. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony- forming cells

20. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors

21. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism

23. Cancer of the ovary.

25. Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

26. The End of a Fantastic Voyage.

27. Challenges Faced by Medical Journals During the COVID-19 Pandemic.

29. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

30. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

34. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

35. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?

39. Reply to C.M. Booth et al.

41. Bevacizumab rechallenge after first line maintenance bevacizumab.

42. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.

43. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

45. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.

46. Phase I studies of drug combinations.

47. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

48. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

49. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.

50. Gene-expression profiling in epithelial ovarian cancer.